Pure Global

Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension - Trial NCT06321705

Access comprehensive clinical trial information for NCT06321705 through Pure Global AI's free database. This phase not specified trial is sponsored by Cereno Scientific AB and is currently Available. The study focuses on Pulmonary Arterial Hypertension.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06321705
Available
drug
Trial Details
ClinicalTrials.gov • NCT06321705
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
Expanded Access, Open-Label, Safety Extension Study for Patients That Have Completed Parent Study CS1-003 and Who Are Judged by the Investigator to Benefit From Continued CS1 Treatment

Study Focus

CS1

drug

Sponsor & Location

Cereno Scientific AB

Gothenburg, Sweden

Timeline & Enrollment

N/A

N/A

N/A

Summary

CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study
 is to evaluate long-term safety and tolerability of continued treatment with CS1.

ICD-10 Classifications

Primary pulmonary hypertension
Other secondary pulmonary hypertension
Pulmonary heart disease and diseases of pulmonary circulation
Stenosis of pulmonary artery
Pulmonary heart disease, unspecified

Data Source

ClinicalTrials.gov

NCT06321705

Non-Device Trial